Back to Conditions

Doravirine: A Newer NNRTI for HIV

Doravirine: A Newer NNRTI for HIV
Prescription Medicines Editorial 30 December 2025

Doravirine is a non-nucleoside reverse transcriptase inhibitor, binding to the enzyme HIV uses to copy its genetic material. It is the newest member of a class that includes efavirenz and rilpivirine, and its advantages are mostly things it does not do: no meal requirement, no restriction on acid-reducing medicines, far fewer psychiatric effects than efavirenz, and a neutral effect on cholesterol. That sounds modest, and in practice it removes several of the things that made the older drugs difficult.

Follow the plan your HIV team gave you. This guide contains no doses.

What it improves on

Compared with efavirenz, the drug it largely replaced, doravirine causes far less in the way of vivid dreams, dizziness, mood disturbance and rash - effects that made efavirenz genuinely unpleasant for many people and led to frequent switching. It also does not raise cholesterol, where efavirenz does.

Compared with rilpivirine, it has no food requirement and, critically, no interaction with proton pump inhibitors. Rilpivirine must be taken with a substantial meal and cannot be taken with a PPI at all - two restrictions that cause real treatment failures. See rilpivirine.

It is also effective across a wider range of baseline viral loads than rilpivirine, which is limited at higher levels.

Taking it

Once daily, with or without food, at roughly the same time each day. It is available alone and as part of a single-tablet regimen with lamivudine and tenofovir disoproxil.

The absence of instructions is the point - there is nothing to arrange around it.

The interaction that does matter

Doravirine is cleared by CYP3A4, so strong enzyme inducers reduce its levels substantially.

Rifampicin and rifabutin are contraindicated, which matters for anyone who might need tuberculosis treatment. So are carbamazepine, phenytoin, phenobarbital and St John's wort.

See carbamazepine and supplements that interfere with your medicines.

Beyond enzyme inducers the interaction profile is relatively clean - considerably cleaner than any boosted regimen. See cobicistat for the contrast.

Tell every prescriber, dentist and pharmacist that you take HIV medication and check anything new, including over-the-counter products.

Resistance

Like other NNRTIs, doravirine has a lower barrier to resistance than integrase inhibitors or boosted protease inhibitors - though its resistance profile differs, and it retains activity against some mutations that compromise efavirenz and rilpivirine.

That is useful for switching, but it does not change the underlying point: intermittent drug levels select resistant virus, and resistance is permanent.

If you are struggling to take it consistently, tell your team rather than rationing. Long-acting injectable options exist - see cabotegravir.

Side effects

Generally well tolerated. Nausea, headache, diarrhoea, fatigue, abnormal dreams and dizziness are the common ones, usually mild and usually early.

Sleep disturbance and mood changes are reported and are worth raising rather than enduring.

Raised liver enzymes occur - report jaundice, dark urine or persistent abdominal pain. See medicines and your liver.

The lipid point

People with HIV now live normal lifespans, so cardiovascular risk over decades matters as much as viral suppression.

Doravirine is neutral on cholesterol and triglycerides, and switching to it from a drug that raises them has been shown to improve lipid profiles. That is a meaningful long-term consideration rather than a cosmetic one.

Lipids, glucose, kidney and liver function are monitored alongside viral load and CD4 count - see monitoring long-term medicines.

Taking it consistently

Because there is no food requirement and no acid restriction, the only thing that matters is taking it at roughly the same time each day.

If you miss a dose, take it when you remember unless it is nearly time for the next - and never double up. Vomiting shortly after a dose is worth asking about rather than guessing. See missed doses.

The hepatitis B point

Doravirine has no activity against hepatitis B. Where it is combined with lamivudine and tenofovir, those components do - and stopping them can cause a severe hepatitis flare in someone with chronic hepatitis B.

Hepatitis B status is checked before starting. See lamivudine.

Where it sits now

Integrase inhibitors are generally first choice for starting HIV treatment, so doravirine is used more often as a switch than as an initial regimen - for people who want to move away from an integrase inhibitor because of weight gain or sleep effects, or away from a boosted regimen because of interactions.

It is a useful option precisely because it sits outside those two groups, and because its interaction profile is clean enough to suit someone on a long list of other medicines.

Undetectable equals untransmittable

A sustained undetectable viral load means HIV cannot be passed on sexually - well established rather than aspirational. See dolutegravir.

HIV treatment and testing are free in the UK regardless of immigration status.

The Conditions section covers more on what medicines are prescribed for - Pembrolizumab: Immunotherapy and Its Side Effects is closely related to this one.